Moleculo

First Investment: 2015

EXIT - Acquisition (Illumina: ILMN)

Moleculo’s founders developed new library prep and analysis techniques that allowed them to assemble short sequences of DNA base-pair information into accurate, synthetic long reads. Illumina acquired the company in 2013.

Explore Companies

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery